Oxford Instruments (United Kingdom)

The magnetic field is an outstanding experimental tool for physics. To go beyond the conventional commercially available superconducting (SC) magnets, very large infrastructures such as the ones gathered within the European Magnetic Field Laboratory (EMFL) are necessary. The SuperEMFL project is a design study aiming at providing the European high field user community with much higher superconducting fields. This is meant to be achieved by combining high temperature superconductor (HTS) insert magnets, an emerging technology that can work in fields above 25T, with low temperature superconductor (LTS) outsert magnets, a technology limited to fields below 25 T. The project has two design magnetic field targets, 32+T and 40+T. The first design target proposed to combined a single stack of HTS pancakes in combination with a 19 T / 150 mm LTS magnet; the second either a similar arrangement at the sake of a narrower central space or a design with two nested HTS coils combined with a 15 T/ 250 mm LTS magnet. The particular choice of the project is to use no insulation but a metallic tape co-wound with the bare HTS tape. This so-called Metal as Insulation (MI) technology enables a self-protection feature of the HTS coil by allowing the electrical bypass of defects as well as better mechanical performances in a very compact winding. The use of HTS inserts introduces a change of paradigm by providing an unprecedented combination of high magnetic field and long measurement times whilst saving vast amounts of energy in operation.

AI promises transformation, but without clear regulation, it risks harm. Can the UK strike the right balance?

Introduction: Knowledge gaps and controversies remain regarding the natural history and variability of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The objectives were to provide an overview of these diseases for the following outcomes of interest: clinical presentation, treatment patterns, and disease burden, including the association between proteinuria and kidney outcomes. Methods: This systematic literature review (SLR) included studies of adults and children with C3G or primary IC-MPGN investigating outcomes of interest. Embase and MEDLINE were searched from January 2012 to February 22, 2024, combining terms for C3G or IC-MPGN and outcomes of interest. Supplementary congress searches and reference list checking of relevant articles were conducted. Study details, outcomes of interest, and key findings were extracted, and data were narratively summarized. Results: In total, 148 articles were included. No clear trend for differences between C3G and primary IC-MPGN were observed for clinical presentation. Treatments included immunosuppressive therapies and off-label anti-complement agents. Kidney failure occurred in up to 50% and 37% of patients with C3G and primary IC-MPGN, respectively, and kidney transplantation was required in up to 32% and 24% of patients, respectively. Mortality was reported in up to 21% of patients. No clear trend of complete remission across treatments was observed. In longitudinal studies, proteinuria was associated with increasing risk of kidney failure. No articles reported on patient quality of life or caregiver burden. Several articles reported an economic burden according to length of hospital stay. Possible limitations include that terms used for electronic searches limited which articles were identified, many studies were retrospective and small (<10 participants), and risk of bias was not performed. Conclusions: This SLR provides insights into C3G and primary IC-MPGN, emphasizing the need for new targeted and effective treatments. Proteinuria was identified to be an acceptable marker in assessing the efficacy of treatments on long-term kidney outcomes.

Abstract Solenoids constructed by assembling ring-shaped bulk high-temperature superconductors (HTSs) have been demonstrated to be capable of trapping a sufficiently strong and uniform magnetic field for nuclear magnetic resonance and magnetic resonance imaging. These systems, however, were magnetised using field cooling, requiring a large and expensive secondary superconducting magnet to generate the external field. Pulsed-field magnetisation (PFM), on the other hand, is a much more economical and practical method to magnetise bulk HTSs, as it can be carried out using a normal conductor (such as copper) to generate a brief pulsed magnetic field. The trapped field following PFM is found to be significantly lower than that achieved with field-cooling. This is due to the large quantity of heat generated within the bulk during the rapid change in the applied field. While this heating effect has been exploited to improve the pulse magnetisation efficiency of disc-shaped bulks, it has proven detrimental when magnetising ring-shaped bulks. Here, we present a refinement of the PFM procedure of ring-shaped bulks that can assist with increasing the trapped field. By inserting bulk HTS discs into the bore of a ring and pulse magnetising the discs before the rings, and subsequently removing the discs, we show that a higher field can be trapped in the ring.

Objectives To perform a systematic literature review (SLR) on hearing and quality-of-life (QoL) benefits of bilateral versus unilateral cochlear implants (CIs) in adults with sensorineural hearing loss (SNHL), and to quantify benefits through a meta-analysis when feasible. Methods Embase, MEDLINE, and Cochrane were searched from January 2005–June 2022. Eligible studies presented effectiveness of CIs and/or QoL of adult CI users. Articles that presented numerical point estimates for, or numerical difference between, bilateral and unilateral CI, and measures of uncertainty were considered for meta-analysis, with data analyzed using fixed- and random-effects models. Results Thirty-five articles were included. There was a trend of significant improvement with bilateral CIs in sound localization and binaural redundancy. A meta-analysis confirmed statistically significant benefits in speech perception (in quiet, 12.6 percentage point [95% confidence interval: 7.1, 18.1] improvement; in noise, improvement in speech reception threshold of 1.5 dB signal-to-noise ratio [–1.5 dB; 95% confidence interval: −2.5, −0.4]). There were beneficial trends of bilateral CIs regarding head-shadow effect and binaural release from masking. Significant improvements in hearing-specific QoL were observed; generic QoL was mostly unchanged. Discussion Bilateral CIs provide audiological benefit over unilateral CI, resulting in hearing-specific QoL improvements. Lack of changes in generic QoL may reflect that instrument domains are insensitive to hearing-related changes when going from unilateral to bilateral CIs. Meta-analyses could not be performed for all hearing and QoL outcomes owing to variability in methodologies across studies. Conclusions These findings should be used to inform clinical decision-making to ensure the best outcomes for adults with bilateral SNHL.

Background: Secondary immunodeficiency disease (SID) is a complex, heterogeneous condition that occurs when extrinsic factors weaken the immune system. Expert consensus guidelines recommend immunoglobulin replacement therapy to manage immunoglobulin G (IgG) levels and mitigate severe, recurrent, and persistent infections. Hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% is a dual-vial unit of IgG and recombinant human hyaluronidase; the latter enables absorption of higher volumes of IgG than conventional subcutaneous therapies. Methods: For this systematic literature review, Embase, MEDLINE®, and the Cochrane Library were searched on 9 August 2023, with supplemental congress searches. Results: Eight studies fulfilled the inclusion criteria, reporting real-world evidence of the clinical effectiveness, safety, and tolerability of fSCIG 10% in 183 patients with SID in Europe from September 2014 to August 2021. The potential causes of SID were primarily hematological malignancies, most commonly chronic lymphocytic leukemia. Treatment was typically administered at 4-week or 3-week intervals, with doses of approximately 0.4 g/kg/month. Infections were rare during follow-up, with numerical reductions observed after fSCIG 10% treatment initiation compared with the period before initiation. Adverse reactions, including local infusion site reactions, and tolerability events were uncommon. Conclusions: Given the recency of fSCIG 10% use in patients with SID, there are opportunities for future research to better understand survival and patient-reported outcomes after receiving this treatment. Despite SID heterogeneity, this study demonstrates the feasibility of fSCIG 10% treatment for this condition.